Phase 2 Study of TLK286 in Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Neoplasms

In brief

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

Key facts

Study ID

NCT00035841

Run by

Telik

People needed

60

Starts

2002-04-01

Expected to finish

2004-07-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic diagnosis of breast cancer
• Metastatic disease
• Measurable or evaluable disease
• No prior chemotherapy regimens
• Age at least 18 years
• Adequate liver and kidney function
• Adequate bone marrow function

You may not qualify if…

• Pregnant or lactating women
• Unstable medical conditions
• Chemotherapy within 14 days of TLK286
• Radiation therapy within 14 days of TLK286
• Hormonal therapy within 14 days of TLK286
• Immunotherapy within 14 days of TLK286
• CNS metastasis unless controlled by treatment

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• Indiana University Medical Center — Indianapolis, Indiana, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.